Soligenix Partners with Sterling Pharma Solutions
U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing
Soligenix, Inc. (NASDAQ: SNGX), a biopharmaceutical company dedicated to addressing rare diseases, has announced a strategic partnership with Sterling Pharma Solutions. This collaboration aims to enhance and scale the production of synthetic hypericin, a crucial active ingredient in its topical drug formulations, specifically designed for treating cutaneous T-cell lymphoma (CTCL) and psoriasis.
Synthetic hypericin plays a significant role in two of Soligenix's innovative products: HyBryte™ and SGX302. HyBryte™ is currently in development for treating early-stage CTCL, while SGX302 targets psoriasis. This partnership with Sterling is expected to optimize the manufacturing processes, thus enabling Good Manufacturing Practices (GMP) for clinical trials. The ultimate goal is to lay the groundwork for a commercial manufacturing agreement that could support future product availability.
Dr. Christopher J. Schaber, President and CEO of Soligenix, expressed enthusiasm about this venture, stating, "We look forward to expanding our synthetic hypericin manufacturing capabilities and building upon our fruitful collaboration with Sterling. Our focus is on advancing HyBryte™ toward commercialization while aiming to reduce production costs."
Advancements in Manufacturing and Research
Sterling Pharma Solutions brings extensive expertise in active pharmaceutical ingredient manufacturing and analytics, which they believe will add significant value to Soligenix's programs. Adam Kujath, Site Head at Sterling, emphasized their commitment to advancing the HyBryte™ program along with Soligenix to ensure success in upcoming Phase 3 clinical trials.
HyBryte™, also known as SGX301, utilizes a pioneering photodynamic therapy approach that safely activates synthetic hypericin via visible light. This method provides an advantage over traditional UV therapies by penetrating deeper skin layers, making it effective for treating thicker lesions associated with CTCL. The treatment cycle has shown promising results in clinical settings, demonstrating significant improvement in patients compared to placebo results.
HyBryte™ treatments aim to reduce the risk of secondary malignancies often associated with conventional therapies. In a notable Phase 2 clinical study, patients treated with topical hypericin exhibited statistically significant improvement in their skin conditions, which reinforces the therapeutic potential of this treatment.
Future Perspectives on HyBryte™ Trials
Following the successful Phase 3 FLASH trial, which included 169 patients, regulatory bodies such as the FDA and EMA indicated that Soligenix must conduct a second Phase 3 trial to support marketing approval. The forthcoming FLASH2 study, set to commence shortly, will employ a similar rigorous design and is anticipated to enroll approximately 80 participants.
This new study aims to provide extended treatment evaluation, offering insights under typical use conditions. Statistical modeling from previous trials suggests a substantially higher response rate in patients completing the treatment, further affirming the prospective approval pathway.
In addition to the ongoing clinical activities, the FDA awarded an Orphan Products Development grant to support HyBryte™ research for CTCL treatment. This grant signifies recognition of the importance of finding effective therapies for patients suffering from this rare disease, underscoring Soligenix's commitment to addressing significant unmet medical needs.
Understanding Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin's lymphoma characterized by a proliferation of malignant T-cells that primarily migrate to the skin, forming lesions that can lead to serious health risks. The progression of CTCL can vary significantly based on the stage at which it is diagnosed, with advanced stages associated with lower survival rates.
Soligenix aims to reshape the treatment landscape for CTCL and psoriasis with innovative therapies capable of offering effective treatments while emphasizing safety and tolerability. The company remains dedicated to its mission of enhancing patient outcomes through groundbreaking research and development.
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. Their current portfolio includes HyBryte™, a novel photodynamic therapy addressing CTCL, and ongoing research into psoriasis treatment methods. The company also explores other biopharmaceutical solutions, including vaccine development targeting biothreats.
For further information about Soligenix, Inc., please visit their official website.
Frequently Asked Questions
What is the significance of the partnership with Sterling Pharma Solutions?
The partnership aims to improve the scalability and efficiency of synthetic hypericin production, which is crucial for Soligenix's drug formulations.
How does HyBryte™ work?
HyBryte™ utilizes photodynamic therapy to activate synthetic hypericin with visible light, targeting malignant T-cells in the skin to treat CTCL.
What were the results of the previous clinical trials?
The previous Phase 2 study demonstrated significant improvements in patients treated with HyBryte™, leading to promising results for Phase 3 trials.
What are the future plans for HyBryte™?
The FLASH2 study aims to enroll patients soon to gather additional data supporting HyBryte™'s efficacy and safety for eventual market approval.
How does Soligenix address the safety concerns associated with treatments for CTCL?
HyBryte™ is designed to be a safer alternative, minimizing risks typically associated with DNA-damaging therapies, providing effective treatment with fewer side effects.
